Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: A multicenter, prospective study

Journal of Andrology

Volumn 33, Issue 3, 2012, Pages 397-403

  Lee, Joo Yong ^a   Park, Sung Yul ^a   Jeong, Tae Yoong ^b   Moon, Hong Sang ^a,c   Kim, Yong Tae ^a   Yoo, Tag Keun ^d   Choi, Hong Yong ^a,c   Park, Hae Young ^a   Lee, Seung Wook ^a,c  

^a Hanyang University College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c Hanyang University Guri Hospital   (South Korea)

^d Eulji General Hospital   (South Korea)

Author keywords

Adrenergic 1 receptor antagonists; Drug therapy; Efficacy; Safety

Indexed keywords

ALFUZOSIN; TADALAFIL; TAMSULOSIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ERECTILE DYSFUNCTION; FACE FLUSHING; FLUSHING; HEART RATE; HUMAN; HYPOTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL INDEX OF ERECTILE FUNCTION 5; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; RESIDUAL URINE; SCORING SYSTEM; SEXUAL FUNCTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINE FLOW RATE; URINE VOLUME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BLOOD PRESSURE; CARBOLINES; DIZZINESS; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART RATE; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 84862565277     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.013185     Document Type: Article

References (27)

1. Ahn TY, Lee DS, Kang WC, Hong JH, Kim YS. Validation of an abridged Korean version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Korean J Urol. 2001;42:535-540.
2. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology. 2004;64:998-1003; discussion 1003-1004.
3. Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH: pilot study. J Sex Med. 2008;5:2170-2178.
4. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332-1336.
5. Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int. 2006;97(suppl 2):39-43; discussion 44-45.
6. Chapple CR. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol. 1996;29:129-144.
7. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59:342-352.
8. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res. 2009;21:122-128.
9. Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2010;183:1092-1097.
10. Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011;107:1110-1116.
11. Giannitsas K, Mitropoulos D, Konstantinopoulos A, Athanasopoulos A, Perimenis P. Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. Expert Opin Pharmacother. 2008;9:1687-1693.
12. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:804-814.
13. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51:1717-1723.
14. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, Pereira A. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol. 2004;172:1935-1940.
15. Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol. 2009;55:38-48.
16. Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, Rellini AH, Segraves T. Definitions/epidemiology/ risk factors for sexual dysfunction. J Sex Med. 2010;7:1598-1607.
17. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction: preliminary report. J Sex Med. 2009;6:544-552.
18. Masson P, Lambert SM, Brown M, Shabsigh R. PDE-5 inhibitors: current status and future trends. Urol Clin North Am. 2005; 32:511-525, viii.
19. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 2000;12(suppl 4):S6-S11.
20. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185: 1793-1803.
21. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401-1407.
22. O'Leary MP. Treatment and pharmacologic management of BPH in the context of common comorbidities. Am J Manag Care. 2006; 12:S129-S140.
23. Park CH, Chang HS, Oh BR, Kim HJ, Sul CK, Chung SK, Jung SI. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a nonblind multicentre Korean study. Clin Drug Investig. 2004;24:41-47.
24. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009;56:727-735.
25. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med. 2009;6:1794-1808; quiz 1793, 1809-1810.
26. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol. 2010;28:17-22.
27. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol. 2010;20:49-54.